Sabestomig

4 trials 1 recruiting

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

1 Recruiting

3 Completed trials

1 Sponsors

7 Countries

Phase II

Phase I/II

Phase I (Other)

Phase I (FiH)

Phase II: 1 Phase I/II: 1 Phase I (Other): 1 Phase I (FiH): 1

Indications tested

Adenocarcinoma gastric 1 Non-small cell lung cancer 1

Sponsors using this IMP

AstraZeneca AB 4

All trials

4 total

Master protocol of novel combinations in participants with locally advanced unresectable or metastatic gastric or gastroesophageal junction … Recruiting

2024-510977-27-00 Phase II 1 country AstraZeneca AB
Phase 1b Study of Dato-DXd in Combination with Immunotherapy with or without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cance… Ended

2023-505992-54-00 Phase I (Other) 4 countries Astrazeneca AB
Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Ended

2022-502773-41-00 Phase I/II 4 countries AstraZeneca AB
A study to assess the safety and efficacy of AZD7789 in participants with advanced or metastatic solid cancer Ended

2022-502774-17-00 Phase I (FiH) 3 countries AstraZeneca AB

Showing 1–4 of 4 trials

← All drugs A–Z